-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The California Institute for Regenerative Medicine (California Institute for Regenerative Medicine) allocated nearly $12 million to support a new clinical trial of cell-based therapies to improve the efficacy and survival of children and young blood cancer patients receiving stem cell transplants
This treatment, named T-allo10, aims to improve the immune response to pathogens and cancer without increasing the possibility of graft-versus-host disease in patients who must receive transplants from an incompletely matched donor
The trial will be led by Maria Grazia Roncarolo, MD, professor of pediatrics and medicine
"In California, approximately 500 children receive stem cell transplants each year.
At present, the treatment standard for many blood cancers is divided into two parts: chemotherapy is used to destroy the patient's cancer cells, and then blood and immune stem cells are transplanted from an immune-matched donor
Roncarolo and her team will test T-allo10, which means that mature immune cells are used simultaneously with type 1 regulatory T cells or Tr1 cells from donors after stem cell transplantation
T-allo10 aims to improve transplant outcomes by reducing cancer recurrence and infection rates and the possibility of graft-versus-host disease
Roncarolo said: "My team and I are very pleased to receive CIRM's support for our immunotherapy clinical trials, which may help leukemia patients receive hematopoietic stem and progenitor cell transplants from non-exactly matched donors-this group continues to suffer Terrible results and high unmet needs